Relevant bibliographies by topics / Extracellular vesicles mimetic-nanovesicles / Journal articles

Journal articles on the topic 'Extracellular vesicles mimetic-nanovesicles'

To see the other types of publications on this topic, follow the link: Extracellular vesicles mimetic-nanovesicles.
Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 17 journal articles for your research on the topic 'Extracellular vesicles mimetic-nanovesicles.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Nasiri Kenari, Amirmohammad, Lesley Cheng, and Andrew F. Hill. "Methods for loading therapeutics into extracellular vesicles and generating extracellular vesicles mimetic-nanovesicles." Methods 177 (May 2020): 103–13. http://dx.doi.org/10.1016/j.ymeth.2020.01.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Martinelli, Carolina, Fabio Gabriele, Elena Dini, Francesca Carriero, Giorgia Bresciani, Bianca Slivinschi, Marco Dei Giudici, et al. "Development of Artificial Plasma Membranes Derived Nanovesicles Suitable for Drugs Encapsulation." Cells 9, no. 7 (July 6, 2020): 1626. http://dx.doi.org/10.3390/cells9071626.

Full text
Abstract:
Extracellular vesicles (EVs) are considered as promising nanoparticle theranostic tools in many pathological contexts. The increasing clinical employment of therapeutic nanoparticles is contributing to the development of a new research area related to the design of artificial EVs. To this aim, different approaches have been described to develop mimetic biologically functional nanovescicles. In this paper, we suggest a simplified procedure to generate plasma membrane-derived nanovesicles with the possibility to efficiently encapsulate different drugs during their spontaneously assembly. After physical and molecular characterization by Tunable Resistive Pulse Sensing (TRPS) technology, transmission electron microscopy, and flow cytometry, as a proof of principle, we have loaded into mimetic EVs the isoquinoline alkaloid Berberine chloride and the chemotherapy compounds Temozolomide or Givinostat. We demonstrated the fully functionality of these nanoparticles in drug encapsulation and cell delivery, showing, in particular, a similar cytotoxic effect of direct cell culture administration of the anticancer drugs. In conclusion, we have documented the possibility to easily generate scalable nanovesicles with specific therapeutic cargo modifications useful in different drug delivery contexts.
APA, Harvard, Vancouver, ISO, and other styles
3

Ailuno, Giorgia, Sara Baldassari, Francesco Lai, Tullio Florio, and Gabriele Caviglioli. "Exosomes and Extracellular Vesicles as Emerging Theranostic Platforms in Cancer Research." Cells 9, no. 12 (December 1, 2020): 2569. http://dx.doi.org/10.3390/cells9122569.

Full text
Abstract:
Exosomes are endosome-derived nanovesicles produced by healthy as well as diseased cells. Their proteic, lipidic and nucleic acid composition is related to the cell of origin, and by vehiculating bioactive molecules they are involved in cell-to-cell signaling, both in healthy and pathologic conditions. Being nano-sized, non-toxic, biocompatible, scarcely immunogenic, and possessing targeting ability and organotropism, exosomes have been proposed as nanocarriers for their potential application in diagnosis and therapy. Among the different techniques exploited for exosome isolation, the sequential ultracentrifugation/ultrafiltration method seems to be the gold standard; alternatively, commercially available kits for exosome selective precipitation from cell culture media are frequently employed. To load a drug or a detectable agent into exosomes, endogenous or exogenous loading approaches have been developed, while surface engineering procedures, such as click chemistry, hydrophobic insertion and exosome display technology, allow for obtaining actively targeted exosomes. This review reports on diagnostic or theranostic platforms based on exosomes or exosome-mimetic vesicles, highlighting the diverse preparation, loading and surface modification methods applied, and the results achieved so far.
APA, Harvard, Vancouver, ISO, and other styles
4

Ng, Chiew Yong, Li Ting Kee, Maimonah Eissa Al-Masawa, Qian Hui Lee, Thayaalini Subramaniam, David Kok, Min Hwei Ng, and Jia Xian Law. "Scalable Production of Extracellular Vesicles and Its Therapeutic Values: A Review." International Journal of Molecular Sciences 23, no. 14 (July 20, 2022): 7986. http://dx.doi.org/10.3390/ijms23147986.

Full text
Abstract:
Extracellular vesicles (EVs) are minute vesicles with lipid bilayer membranes. EVs are secreted by cells for intercellular communication. Recently, EVs have received much attention, as they are rich in biological components such as nucleic acids, lipids, and proteins that play essential roles in tissue regeneration and disease modification. In addition, EVs can be developed as vaccines against cancer and infectious diseases, as the vesicle membrane has an abundance of antigenic determinants and virulent factors. EVs for therapeutic applications are typically collected from conditioned media of cultured cells. However, the number of EVs secreted by the cells is limited. Thus, it is critical to devise new strategies for the large-scale production of EVs. Here, we discussed the strategies utilized by researchers for the scalable production of EVs. Techniques such as bioreactors, mechanical stimulation, electrical stimulation, thermal stimulation, magnetic field stimulation, topographic clue, hypoxia, serum deprivation, pH modification, exposure to small molecules, exposure to nanoparticles, increasing the intracellular calcium concentration, and genetic modification have been used to improve the secretion of EVs by cultured cells. In addition, nitrogen cavitation, porous membrane extrusion, and sonication have been utilized to prepare EV-mimetic nanovesicles that share many characteristics with naturally secreted EVs. Apart from inducing EV production, these upscaling interventions have also been reported to modify the EVs’ cargo and thus their functionality and therapeutic potential. In summary, it is imperative to identify a reliable upscaling technique that can produce large quantities of EVs consistently. Ideally, the produced EVs should also possess cargo with improved therapeutic potential.
APA, Harvard, Vancouver, ISO, and other styles
5

Oshchepkova, Anastasiya, Oleg Markov, Evgeniy Evtushenko, Alexander Chernonosov, Elena Kiseleva, Ksenia Morozova, Vera Matveeva, Lyudmila Artemyeva, Valentin Vlassov, and Marina Zenkova. "Tropism of Extracellular Vesicles and Cell-Derived Nanovesicles to Normal and Cancer Cells: New Perspectives in Tumor-Targeted Nucleic Acid Delivery." Pharmaceutics 13, no. 11 (November 11, 2021): 1911. http://dx.doi.org/10.3390/pharmaceutics13111911.

Full text
Abstract:
The main advantage of extracellular vesicles (EVs) as a drug carrier system is their low immunogenicity and internalization by mammalian cells. EVs are often considered a cell-specific delivery system, but the production of preparative amounts of EVs for therapeutic applications is challenging due to their laborious isolation and purification procedures. Alternatively, mimetic vesicles prepared from the cellular plasma membrane can be used in the same way as natural EVs. For example, a cytoskeleton-destabilizing agent, such as cytochalasin B, allows the preparation of membrane vesicles by a series of centrifugations. Here, we prepared cytochalasin-B-inducible nanovesicles (CINVs) of various cellular origins and studied their tropism in different mammalian cells. We observed that CINVs derived from human endometrial mesenchymal stem cells exhibited an enhanced affinity to epithelial cancer cells compared to myeloid, lymphoid or neuroblastoma cancer cells. The dendritic cell-derived CINVs were taken up by all studied cell lines with a similar efficiency that differed from the behavior of DC-derived EVs. The ability of cancer cells to internalize CINVs was mainly determined by the properties of recipient cells, and the cellular origin of CINVs was less important. In addition, receptor-mediated interactions were shown to be necessary for the efficient uptake of CINVs. We found that CINVs, derived from late apoptotic/necrotic cells (aCINVs) are internalized by in myelogenous (K562) 10-fold more efficiently than CINVs, and interact much less efficiently with melanocytic (B16) or epithelial (KB-3-1) cancer cells. Finally, we found that CINVs caused a temporal and reversible drop of the rate of cell division, which restored to the level of control cells with a 24 h delay.
APA, Harvard, Vancouver, ISO, and other styles
6

Anita, Limanjaya, Guo Nan Yin, Soon-Sun Hong, Ju-Hee Kang, Yong Song Gho, Jun-Kyu Suh, and Ji-Kan Ryu. "Pericyte-derived extracellular vesicle-mimetic nanovesicles ameliorate erectile dysfunction via lipocalin 2 in diabetic mice." International Journal of Biological Sciences 18, no. 9 (2022): 3653–67. http://dx.doi.org/10.7150/ijbs.72243.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kim, Yoon Seon, Gyeongyun Go, Chul-Won Yun, Ji-Hye Yea, Sungtae Yoon, Su-Yeon Han, Gaeun Lee, Mi-Young Lee, and Sang Hun Lee. "Topical Administration of Melatonin-Loaded Extracellular Vesicle-Mimetic Nanovesicles Improves 2,4-Dinitrofluorobenzene-Induced Atopic Dermatitis." Biomolecules 11, no. 10 (October 2, 2021): 1450. http://dx.doi.org/10.3390/biom11101450.

Full text
Abstract:
Atopic dermatitis (AD) is caused by multiple factors that trigger chronic skin inflammation, including a defective skin barrier, immune cell activation, and microbial exposure. Although melatonin has an excellent biosafety profile and a potential to treat AD, there is limited clinical evidence from controlled trials that support the use of melatonin as an AD treatment. The delivery of melatonin via the transdermal delivery system is also a challenge in designing melatonin-based AD treatments. In this study, we generated melatonin-loaded extracellular vesicle-mimetic nanoparticles (MelaNVs) to improve the transdermal delivery of melatonin and to evaluate their therapeutic potential in AD. The MelaNVs were spherical nanoparticles with an average size of 100 nm, which is the optimal size for the transdermal delivery of drugs. MelaNVs showed anti-inflammatory effects by suppressing the release of TNF-α and β-hexosaminidase in LPS-treated RAW264.7 cells and compound 48/80-treated RBL-2H3 cells, respectively. MelaNVs showed a superior suppressive effect compared to an equivalent concentration of free melatonin. Treating a 2,4-dinitrofluorobenzene (DNCB)-induced AD-like mouse model with MelaNVs improved AD by suppressing local inflammation, mast cell infiltration, and fibrosis. In addition, MelaNVs effectively suppressed serum IgE levels and regulated serum IFN-γ and IL-4 levels. Taken together, these results suggest that MelaNVs are novel and efficient transdermal delivery systems of melatonin and that MelaNVs can be used as a treatment to improve AD.
APA, Harvard, Vancouver, ISO, and other styles
8

Tao, Shi-Cong, Bi-Yu Rui, Qi-Yang Wang, Ding Zhou, Yang Zhang, and Shang-Chun Guo. "Extracellular vesicle-mimetic nanovesicles transport LncRNA-H19 as competing endogenous RNA for the treatment of diabetic wounds." Drug Delivery 25, no. 1 (January 1, 2018): 241–55. http://dx.doi.org/10.1080/10717544.2018.1425774.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Oh, Keunhee, Sae Rom Kim, Dae-Kyum Kim, Myung Won Seo, Changjin Lee, Hak Mo Lee, Ju-Eun Oh, et al. "In Vivo Differentiation of Therapeutic Insulin-Producing Cells from Bone Marrow Cells via Extracellular Vesicle-Mimetic Nanovesicles." ACS Nano 9, no. 12 (November 3, 2015): 11718–27. http://dx.doi.org/10.1021/acsnano.5b02997.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Yin, Guo Nan, Soo-Hwan Park, Jiyeon Ock, Min-Ji Choi, Anita Limanjaya, Kalyan Ghatak, Kang-Moon Song, et al. "Pericyte-Derived Extracellular Vesicle–Mimetic Nanovesicles Restore Erectile Function by Enhancing Neurovascular Regeneration in a Mouse Model of Cavernous Nerve Injury." Journal of Sexual Medicine 17, no. 11 (November 2020): 2118–28. http://dx.doi.org/10.1016/j.jsxm.2020.07.083.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Zhao, Qingguo, Bo Hai, Jack Kelly, Samuel Wu, and Fei Liu. "Extracellular vesicle mimics made from iPS cell-derived mesenchymal stem cells improve the treatment of metastatic prostate cancer." Stem Cell Research & Therapy 12, no. 1 (January 7, 2021). http://dx.doi.org/10.1186/s13287-020-02097-5.

Full text
Abstract:
Abstract Background Extracellular vesicles (EVs) and their mimics from mesenchymal stem cells (MSCs) are promising drug carriers to improve cancer treatment, but their application is hindered by donor variations and expansion limitations of conventional tissue-derived MSCs. To circumvent these issues, we made EV-mimicking nanovesicles from standardized MSCs derived from human induced pluripotent stem cells (iPSCs) with a theoretically limitless expandability, and examined the targeting capacity of these nanovesicles to prostate cancer. Methods Nanovesicles are made from intact iPSC-MSCs through serial extrusion. The selective uptake of fluorescently labeled nanovesicles by prostate cancer cells vs. non-tumor cells was examined with flow cytometry. For in vivo tracing, nanovesicles were labeled with fluorescent dye DiR or renilla luciferase. In mice carrying subcutaneous or bone metastatic PC3 prostate cancer, the biodistribution of systemically infused nanovesicles was examined with in vivo and ex vivo imaging of DiR and luminescent signals. A chemotherapeutic drug, docetaxel, was loaded into nanovesicles during extrusion. The cytotoxicities of nanovesicle-encapsulated docetaxel on docetaxel-sensitive and -resistant prostate cancer cells and non-tumor cells were examined in comparison with free docetaxel. Therapeutic effects of nanovesicle-encapsulated docetaxel were examined in mice carrying subcutaneous or bone metastatic prostate cancer by monitoring tumor growth in comparison with free docetaxel. Results iPSC-MSC nanovesicles are more selectively taken up by prostate cancer cells vs. non-tumor cells in vitro compared with EVs, membrane-only EV-mimetic nanoghosts and liposomes, which is not affected by storage for up to 6 weeks. In mouse models of subcutaneous and bone metastatic PC3 prostate cancer, systemically infused nanovesicles accumulate in tumor regions with significantly higher selectivity than liposomes. The loading of docetaxel into nanovesicles was efficient and did not affect the selective uptake of nanovesicles by prostate cancer cells. The cytotoxicities of nanovesicle-encapsulated docetaxel are significantly stronger on docetaxel-resistant prostate cancer cells and weaker on non-tumor cells than free docetaxel. In mouse models of subcutaneous and bone metastatic prostate cancer, nanovesicle-encapsulated docetaxel significantly decreased the tumor growth and toxicity to white blood cells compared with free docetaxel. Conclusions Our data indicate that EV-mimicking iPSC-MSC nanovesicles are promising to improve the treatment of metastatic prostate cancer.
APA, Harvard, Vancouver, ISO, and other styles
12

Yin, Guo, Tae Shin, Jiyeon Ock, Min-Ji Choi, Anita Limanjaya, Mi-Hye Kwon, Fang-Yuan Liu, et al. "Pericyte‑derived extracellular vesicles‑mimetic nanovesicles improves peripheral nerve regeneration in mouse models of sciatic nerve transection." International Journal of Molecular Medicine 49, no. 2 (December 17, 2021). http://dx.doi.org/10.3892/ijmm.2021.5073.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Bandeira, Elga, Su Chul Jang, Cecilia Lässer, Kristina Johansson, Madeleine Rådinger, and Kyong-Su Park. "Effects of mesenchymal stem cell-derived nanovesicles in experimental allergic airway inflammation." Respiratory Research 24, no. 1 (January 5, 2023). http://dx.doi.org/10.1186/s12931-023-02310-y.

Full text
Abstract:
Abstract Background Allergic asthma is associated with airflow obstruction and hyper-responsiveness that arises from airway inflammation and remodeling. Cell therapy with mesenchymal stem cells (MSC) has been shown to attenuate inflammation in asthma models, and similar effects have recently been observed using extracellular vesicles (EV) obtained from these cells. Biologically functional vesicles can also be artificially generated from MSC by extruding cells through membranes to produce EV-mimetic nanovesicles (NV). In this study, we aimed to determine the effects of different MSC-derived vesicles in a murine model of allergic airway inflammation. Methods EV were obtained through sequential centrifugation of serum-free media conditioned by human bone marrow MSC for 24 h. NV were produced through serial extrusion of the whole cells through filters. Both types of vesicles underwent density gradient purification and were quantified through nanoparticle tracking analysis. C57BL/6 mice were sensitized to ovalbumin (OVA, 8 µg), and then randomly divided into the OVA group (intranasally exposed to 100 µg OVA for 5 days) and control group (exposed to PBS). The mice were then further divided into groups that received 2 × 109 EV or NV (intranasally or intraperitoneally) or PBS immediately following the first OVA exposure. Results Administration of EV and NV reduced cellularity and eosinophilia in bronchoalveolar lavage (BAL) fluid in OVA-sensitized and OVA-exposed mice. In addition, NV treatment resulted in decreased numbers of inflammatory cells within the lung tissue, and this was associated with lower levels of Eotaxin-2 in both BAL fluid and lung tissue. Furthermore, both intranasal and systemic administration of NV were effective in reducing inflammatory cells; however, systemic delivery resulted in a greater reduction of eosinophilia in the lung tissue. Conclusions Taken together, our results indicate that MSC-derived NV significantly reduce OVA-induced allergic airway inflammation to a level comparable to EV. Thus, cell-derived NV may be a novel EV-mimetic therapeutic candidate for treating allergic diseases such as asthma.
APA, Harvard, Vancouver, ISO, and other styles
14

Kwon, Mi-Hye, Kang-Moon Song, Anita Limanjaya, Min-Ji Choi, Kalyan Ghatak, Nhat Minh Nguyen, Jiyeon Ock, et al. "Embryonic stem cell-derived extracellular vesicle-mimetic nanovesicles rescue erectile function by enhancing penile neurovascular regeneration in the streptozotocin-induced diabetic mouse." Scientific Reports 9, no. 1 (December 2019). http://dx.doi.org/10.1038/s41598-019-54431-4.

Full text
Abstract:
AbstractExtracellular vesicles (EVs) have attracted particular interest in various fields of biology and medicine. However, one of the major hurdles in the clinical application of EV-based therapy is their low production yield. We recently developed cell-derived EV-mimetic nanovesicles (NVs) by extruding cells serially through filters with diminishing pore sizes (10, 5, and 1 μm). Here, we demonstrate in diabetic mice that embryonic stem cell (ESC)-derived EV-mimetic NVs (ESC-NVs) completely restore erectile function (~96% of control values) through enhanced penile angiogenesis and neural regeneration in vivo, whereas ESC partially restores erectile function (~77% of control values). ESC-NVs promoted tube formation in primary cultured mouse cavernous endothelial cells and pericytes under high-glucose condition in vitro; and accelerated microvascular and neurite sprouting from aortic ring and major pelvic ganglion under high-glucose condition ex vivo, respectively. ESC-NVs enhanced the expression of angiogenic and neurotrophic factors (hepatocyte growth factor, angiopoietin-1, nerve growth factor, and neurotrophin-3), and activated cell survival and proliferative factors (Akt and ERK). Therefore, it will be a better strategy to use ESC-NVs than ESCs in patients with erectile dysfunction refractory to pharmacotherapy, although it remains to be solved for future clinical application of ESC.
APA, Harvard, Vancouver, ISO, and other styles
15

Cao, Lei, Tian Tian, Yuanbo Huang, Shiqin Tao, Xiaohong Zhu, Mifang Yang, Jing Gu, et al. "Neural progenitor cell-derived nanovesicles promote hair follicle growth via miR-100." Journal of Nanobiotechnology 19, no. 1 (January 11, 2021). http://dx.doi.org/10.1186/s12951-020-00757-5.

Full text
Abstract:
Abstract Background Accumulating evidence shows that mesenchymal stem cell-derived extracellular vesicles (EVs) hold great promise to promote hair growth. However, large-scale production of EVs is still a challenge. Recently, exosome-mimetic nanovesicles (NV) prepared by extruding cells have emerged as an alternative strategy for clinical-scale production. Here, ReNcell VM (ReN) cells, a neural progenitor cell line was serially extruded to produce NV. Results ReN-NV were found to promote dermal papilla cell (DPC) proliferation. In addition, in a mouse model of depilation-induced hair regeneration, ReN-NV were injected subcutaneously, resulting in an acceleration of hair follicle (HF) cycling transition at the site. The underlying mechanism was indicated to be the activation of Wnt/β-catenin signaling pathway. Furthermore, miR-100 was revealed to be abundant in ReN-NV and significantly up-regulated in DPCs receiving ReN-NV treatment. miR-100 inhibition verified its important role in ReN-NV-induced β-catenin signaling activation. Conclusion These results provide an alternative agent to EVs and suggest a strategy for hair growth therapy.
APA, Harvard, Vancouver, ISO, and other styles
16

Yin, Guo Nan, Shuguang Piao, Zhiyong Liu, Lei Wang, Jiyeon Ock, Mi-Hye Kwon, Do-Kyun Kim, Yong Song Gho, Jun-Kyu Suh, and Ji-Kan Ryu. "RNA-sequencing profiling analysis of pericyte-derived extracellular vesicle–mimetic nanovesicles-regulated genes in primary cultured fibroblasts from normal and Peyronie’s disease penile tunica albuginea." BMC Urology 21, no. 1 (August 6, 2021). http://dx.doi.org/10.1186/s12894-021-00872-x.

Full text
Abstract:
Abstract Background Peyronie’s disease (PD) is a severe fibrotic disease of the tunica albuginea that causes penis curvature and leads to penile pain, deformity, and erectile dysfunction. The role of pericytes in the pathogenesis of fibrosis has recently been determined. Extracellular vesicle (EV)–mimetic nanovesicles (NVs) have attracted attention regarding intercellular communication between cells in the field of fibrosis. However, the global gene expression of pericyte-derived EV–mimetic NVs (PC–NVs) in regulating fibrosis remains unknown. Here, we used RNA-sequencing technology to investigate the potential target genes regulated by PC–NVs in primary fibroblasts derived from human PD plaque. Methods Human primary fibroblasts derived from normal and PD patients was cultured and treated with cavernosum pericytes isolated extracellular vesicle (EV)–mimetic nanovesicles (NVs). A global gene expression RNA-sequencing assay was performed on normal fibroblasts, PD fibroblasts, and PD fibroblasts treated with PC–NVs. Reverse transcription polymerase chain reaction (RT-PCR) was used for sequencing data validation. Results A total of 4135 genes showed significantly differential expression in the normal fibroblasts, PD fibroblasts, and PD fibroblasts treated with PC–NVs. However, only 91 contra-regulated genes were detected among the three libraries. Furthermore, 20 contra-regulated genes were selected and 11 showed consistent changes in the RNA-sequencing assay, which were validated by RT-PCR. Conclusion The gene expression profiling results suggested that these validated genes may be good targets for understanding potential mechanisms and conducting molecular studies into PD.
APA, Harvard, Vancouver, ISO, and other styles
17

Go, Gyeongyun, Jaewook Lee, Dong‐Sic Choi, Sang Soo Kim, and Yong Song Gho. "Extracellular Vesicle–Mimetic Ghost Nanovesicles for Delivering Anti‐Inflammatory Drugs to Mitigate Gram‐Negative Bacterial Outer Membrane Vesicle–Induced Systemic Inflammatory Response Syndrome." Advanced Healthcare Materials, December 14, 2018, 1801082. http://dx.doi.org/10.1002/adhm.201801082.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography